While p-values alone are insufficient to assess clinical efficacy, meaningful improvements in NAFLD management typically require:a BMI reduction of at least 5%, an ALT decrease of ≥17 U/L, a relative MRI-PDFF reduction of ≥30%, a wc reduction of at least 5 cm, and an overall weight loss of 5–10% (1, 33, 34). Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.